As an early funder of Entrada Therapeutics, we are pleased to share their latest newsletter to the Duchenne community. This update includes news that after review of all the data in the first dose (5 mg/kg) cohort of the ELEVATE-45-201 study for individuals amenable to skipping exon 45, an independent data monitoring committee has recommended dose escalation up to 10mg/kg for a second cohort. The company is on track to report data from Cohort 1 in mid-2026.
Link to community newsletter: https://us8.campaign-archive.com/?u=17d71fdc6c0bc448a2c3a260c&id=87546b3f50
Link to press release: https://ir.entradatx.com/news-releases/news-release-details/independent-safety-data-monitoring-committee-recommends
The post Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45 appeared first on CureDuchenne.